342 related articles for article (PubMed ID: 27721149)
21. In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model.
Mandt REK; Lafuente-Monasterio MJ; Sakata-Kato T; Luth MR; Segura D; Pablos-Tanarro A; Viera S; Magan N; Ottilie S; Winzeler EA; Lukens AK; Gamo FJ; Wirth DF
Sci Transl Med; 2019 Dec; 11(521):. PubMed ID: 31801884
[TBL] [Abstract][Full Text] [Related]
22. Malarial dihydroorotate dehydrogenase. Substrate and inhibitor specificity.
Baldwin J; Farajallah AM; Malmquist NA; Rathod PK; Phillips MA
J Biol Chem; 2002 Nov; 277(44):41827-34. PubMed ID: 12189151
[TBL] [Abstract][Full Text] [Related]
23. Deciphering Interactions between Potential Inhibitors and the
Lima Costa AH; Bezerra KS; de Lima Neto JX; Oliveira JIN; Galvão DS; Fulco UL
J Phys Chem B; 2023 Nov; 127(44):9461-9475. PubMed ID: 37897437
[TBL] [Abstract][Full Text] [Related]
24. Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series.
Palmer MJ; Deng X; Watts S; Krilov G; Gerasyuto A; Kokkonda S; El Mazouni F; White J; White KL; Striepen J; Bath J; Schindler KA; Yeo T; Shackleford DM; Mok S; Deni I; Lawong A; Huang A; Chen G; Wang W; Jayaseelan J; Katneni K; Patil R; Saunders J; Shahi SP; Chittimalla R; Angulo-Barturen I; Jiménez-Díaz MB; Wittlin S; Tumwebaze PK; Rosenthal PJ; Cooper RA; Aguiar ACC; Guido RVC; Pereira DB; Mittal N; Winzeler EA; Tomchick DR; Laleu B; Burrows JN; Rathod PK; Fidock DA; Charman SA; Phillips MA
J Med Chem; 2021 May; 64(9):6085-6136. PubMed ID: 33876936
[TBL] [Abstract][Full Text] [Related]
25. In silico identification of novel inhibitors against Plasmodium falciparum dihydroorate dehydrogenase.
Wadood A; Ulhaq ZU
J Mol Graph Model; 2013 Mar; 40():40-7. PubMed ID: 23353582
[TBL] [Abstract][Full Text] [Related]
26. Original 2-(3-Alkoxy-1H-pyrazol-1-yl)azines Inhibitors of Human Dihydroorotate Dehydrogenase (DHODH).
Lucas-Hourani M; Munier-Lehmann H; El Mazouni F; Malmquist NA; Harpon J; Coutant EP; Guillou S; Helynck O; Noel A; Scherf A; Phillips MA; Tangy F; Vidalain PO; Janin YL
J Med Chem; 2015 Jul; 58(14):5579-98. PubMed ID: 26079043
[TBL] [Abstract][Full Text] [Related]
27. Novel selective and potent inhibitors of malaria parasite dihydroorotate dehydrogenase: discovery and optimization of dihydrothiophenone derivatives.
Xu M; Zhu J; Diao Y; Zhou H; Ren X; Sun D; Huang J; Han D; Zhao Z; Zhu L; Xu Y; Li H
J Med Chem; 2013 Oct; 56(20):7911-24. PubMed ID: 24073986
[TBL] [Abstract][Full Text] [Related]
28. A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria.
Phillips MA; Lotharius J; Marsh K; White J; Dayan A; White KL; Njoroge JW; El Mazouni F; Lao Y; Kokkonda S; Tomchick DR; Deng X; Laird T; Bhatia SN; March S; Ng CL; Fidock DA; Wittlin S; Lafuente-Monasterio M; Benito FJ; Alonso LM; Martinez MS; Jimenez-Diaz MB; Bazaga SF; Angulo-Barturen I; Haselden JN; Louttit J; Cui Y; Sridhar A; Zeeman AM; Kocken C; Sauerwein R; Dechering K; Avery VM; Duffy S; Delves M; Sinden R; Ruecker A; Wickham KS; Rochford R; Gahagen J; Iyer L; Riccio E; Mirsalis J; Bathhurst I; Rueckle T; Ding X; Campo B; Leroy D; Rogers MJ; Rathod PK; Burrows JN; Charman SA
Sci Transl Med; 2015 Jul; 7(296):296ra111. PubMed ID: 26180101
[TBL] [Abstract][Full Text] [Related]
29. Development of a biomarker to monitor target engagement after treatment with dihydroorotate dehydrogenase inhibitors.
Pontikos MA; Leija C; Zhao Z; Wang X; Kilgore J; Tornesi B; Adenmatten N; Phillips MA; Williams NS
Biochem Pharmacol; 2022 Oct; 204():115237. PubMed ID: 36055381
[TBL] [Abstract][Full Text] [Related]
30. Fluorine modulates species selectivity in the triazolopyrimidine class of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors.
Deng X; Kokkonda S; El Mazouni F; White J; Burrows JN; Kaminsky W; Charman SA; Matthews D; Rathod PK; Phillips MA
J Med Chem; 2014 Jun; 57(12):5381-94. PubMed ID: 24801997
[TBL] [Abstract][Full Text] [Related]
31. High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.
Baldwin J; Michnoff CH; Malmquist NA; White J; Roth MG; Rathod PK; Phillips MA
J Biol Chem; 2005 Jun; 280(23):21847-53. PubMed ID: 15795226
[TBL] [Abstract][Full Text] [Related]
32. A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria.
Phillips MA; White KL; Kokkonda S; Deng X; White J; El Mazouni F; Marsh K; Tomchick DR; Manjalanagara K; Rudra KR; Wirjanata G; Noviyanti R; Price RN; Marfurt J; Shackleford DM; Chiu FC; Campbell M; Jimenez-Diaz MB; Bazaga SF; Angulo-Barturen I; Martinez MS; Lafuente-Monasterio M; Kaminsky W; Silue K; Zeeman AM; Kocken C; Leroy D; Blasco B; Rossignol E; Rueckle T; Matthews D; Burrows JN; Waterson D; Palmer MJ; Rathod PK; Charman SA
ACS Infect Dis; 2016 Dec; 2(12):945-957. PubMed ID: 27641613
[TBL] [Abstract][Full Text] [Related]
33. Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice.
Gujjar R; Marwaha A; El Mazouni F; White J; White KL; Creason S; Shackleford DM; Baldwin J; Charman WN; Buckner FS; Charman S; Rathod PK; Phillips MA
J Med Chem; 2009 Apr; 52(7):1864-72. PubMed ID: 19296651
[TBL] [Abstract][Full Text] [Related]
34. Identification and Mechanistic Understanding of Dihydroorotate Dehydrogenase Point Mutations in Plasmodium falciparum that Confer in Vitro Resistance to the Clinical Candidate DSM265.
White J; Dhingra SK; Deng X; El Mazouni F; Lee MCS; Afanador GA; Lawong A; Tomchick DR; Ng CL; Bath J; Rathod PK; Fidock DA; Phillips MA
ACS Infect Dis; 2019 Jan; 5(1):90-101. PubMed ID: 30375858
[TBL] [Abstract][Full Text] [Related]
35. Novel inhibitors of the Plasmodium falciparum electron transport chain.
Stocks PA; Barton V; Antoine T; Biagini GA; Ward SA; O'Neill PM
Parasitology; 2014 Jan; 141(1):50-65. PubMed ID: 24401337
[TBL] [Abstract][Full Text] [Related]
36. A novel series of human dihydroorotate dehydrogenase inhibitors discovered by in vitro screening: inhibition activity and crystallographic binding mode.
Zeng T; Zuo Z; Luo Y; Zhao Y; Yu Y; Chen Q
FEBS Open Bio; 2019 Aug; 9(8):1348-1354. PubMed ID: 31087527
[TBL] [Abstract][Full Text] [Related]
37. Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum.
Phillips MA; Gujjar R; Malmquist NA; White J; El Mazouni F; Baldwin J; Rathod PK
J Med Chem; 2008 Jun; 51(12):3649-53. PubMed ID: 18522386
[TBL] [Abstract][Full Text] [Related]
38. In-Silico molecular docking and simulation studies on novel chalcone and flavone hybrid derivatives with 1, 2, 3-triazole linkage as vital inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.
Thillainayagam M; Malathi K; Ramaiah S
J Biomol Struct Dyn; 2018 Nov; 36(15):3993-4009. PubMed ID: 29132266
[TBL] [Abstract][Full Text] [Related]
39. Tetrahydro-1H,5H-pyrazolo[1,2-a]pyrazole-1-carboxylates as inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.
Strašek N; Lavrenčič L; Oštrek A; Slapšak D; Grošelj U; Klemenčič M; Brodnik Žugelj H; Wagger J; Novinec M; Svete J
Bioorg Chem; 2019 Aug; 89():102982. PubMed ID: 31132601
[TBL] [Abstract][Full Text] [Related]
40. QSAR study on the antimalarial activity of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors.
Hou X; Chen X; Zhang M; Yan A
SAR QSAR Environ Res; 2016; 27(2):101-24. PubMed ID: 26911561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]